{
  "id": 9852821,
  "title": "Klaviyo director Ed Hallen sells $22,126 in company stock",
  "url": "https://urgent.news/2026/09/25/klaviyo-director-ed-hallen-sells-22-126-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-25T22:16:08.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/klaviyo-director-ed-hallen-sells-22126-in-company-stock-93CH-4918254"
  },
  "original_language": "en",
  "account": "Klaviyo's Director and 10% Owner, Ed Hallen, sold 1,300 shares of the company's Series A Common Stock for a total of $22,126 on September 24, 2026. The shares were traded at a weighted average price of $17.02, with individual transactions ranging from $17.00 to $17.03 per share. This sale was conducted according to a pre-approved Rule 10b5-1 trading plan that Hallen established on June 1, 2026. Klaviyo's stock price has fallen by over 51% year-to-date, but InvestingPro analysts believe the stock is currently undervalued, trading below its Fair Value. Of the shares sold, 500 were sold individually for approximately $8,510, while 93,957 shares are indirectly beneficially owned by Hodgkins Trust for Hallen's family. An additional 800 shares were sold for around $13,616, leaving 446,946 shares indirectly owned by Hodgkins LLC, where Hallen serves as manager. Hallen has no direct beneficial ownership of shares held by Hodgkins Trust or Hodgkins LLC, except for his financial interest. For more detailed insights into Klaviyo's valuation and growth potential, investors can refer to the Pro Research Report available exclusively on InvestingPro, which also provides ProTips and essential financial metrics. Klaviyo Inc has recently received updates from various analyst firms following key events and meetings. TD Cowen lowered its price target to $26, citing margin pressures, despite keeping a Buy rating. The firm praised Klaviyo's 26% revenue growth in Q2, surpassing expectations by 2%. Needham maintained a Buy rating with a $30 price target, highlighting Klaviyo's AI adoption progress and enterprise segment strategy after recent investor meetings. Stifel also kept a Buy rating with a $22 price target, noting that Klaviyo's K:BOS conference product announcements align with industry trends. Needham also noticed AI-focused product innovations at the conference, which they believe are gaining attention. Citi reiterated a Buy rating with a $36 price target, following discussions with Klaviyo's leadership about enterprise growth and AI optimization. These updates underline Klaviyo's ongoing efforts to enhance its product offerings and expand its market presence.",
  "summary": null,
  "key_points": [
    "Ed Hallen sold 1,300 shares of Klaviyo stock for $22,126 on September 24, 2026",
    "Sale conducted via pre-approved Rule 10b5-1 trading plan established June 1, 2026",
    "Klaviyo stock price down 51% year-to-date, analysts see it undervalued"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}